Joji Mori

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer

Yutaka Fujiwara, Kenji Tamura, Shunsuke Kondo et al. · Cancer Chemotherapy and Pharmacology · 2016 · 61 citations

Medicine, Oncology, Pharmacology +15

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

Yu Nakamura, Yukimichi Imai, Masahiro Shigeta et al. · Dementia and Geriatric Cognitive Disorders Extra · 2011 · 50 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors

Toshihiko Doi, Masaomi Tajimi, Joji Mori et al. · Investigational New Drugs · 2020 · 30 citations · Full text

Medicine, Oncology, Pharmacology +11

Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Masato Takahashi, Eriko Tokunaga, Joji Mori et al. · Breast Cancer · 2021 · 30 citations · Full text

Medicine, Oncology, Pharmacology +16

Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy

Kenichi Inoue, Norikazu Masuda, Hiroji Iwata et al. · Breast Cancer · 2021 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17